NIH trial: Gilead’s drug works best in COVID patients on oxygen

The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc’s remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation. Read More

More: https://ift.tt/2XlzzIS

Comment or Tag a Friend!

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.